Literature DB >> 5391692

[Lymphography in the evaluation of various radical operations].

T Kolodziejski, A Klein, M Nowacki.   

Abstract

Mesh：

Year:  1969        PMID： 5391692

Source DB:  PubMed          Journal:  Pol Tyg Lek        ISSN： 0032-3756


× No keyword cloud information.
  20 in total

Review 1.  Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.

Authors:  Ali Pourvaziri; Anushri Parakh; Pierpaolo Biondetti; Dushyant Sahani; Avinash Kambadakone
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 2.  Genomics-guided pre-clinical development of cancer therapies.

Authors:  Hayley E Francies; Ultan McDermott; Mathew J Garnett
Journal:  Nat Cancer       Date:  2020-05-22

Review 3.  The application of oncolytic viruses in cancer therapy.

Authors:  Yang Gao; Yan Wu; Tian Huan; Xiaoyan Wang; Jun Xu; Qinggang Xu; Feng Yu; Haifeng Shi
Journal:  Biotechnol Lett       Date:  2021-08-26       Impact factor: 2.461

4.  The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.

Authors:  Shogo Kumagai; Yosuke Togashi; Takahiro Kamada; Eri Sugiyama; Hitomi Nishinakamura; Yoshiko Takeuchi; Kochin Vitaly; Kota Itahashi; Yuka Maeda; Shigeyuki Matsui; Takuma Shibahara; Yasuho Yamashita; Takuma Irie; Ayaka Tsuge; Shota Fukuoka; Akihito Kawazoe; Hibiki Udagawa; Keisuke Kirita; Keiju Aokage; Genichiro Ishii; Takeshi Kuwata; Kenta Nakama; Masahito Kawazu; Toshihide Ueno; Naoya Yamazaki; Koichi Goto; Masahiro Tsuboi; Hiroyuki Mano; Toshihiko Doi; Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Nat Immunol       Date:  2020-08-31       Impact factor: 25.606

Review 5.  Vessel co-option in cancer.

Authors:  Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds
Journal:  Nat Rev Clin Oncol       Date:  2019-08       Impact factor: 66.675

Review 6.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

7.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.

Authors:  Peng Jiang; Shengqing Gu; Deng Pan; Jingxin Fu; Avinash Sahu; Xihao Hu; Ziyi Li; Nicole Traugh; Xia Bu; Bo Li; Jun Liu; Gordon J Freeman; Myles A Brown; Kai W Wucherpfennig; X Shirley Liu
Journal:  Nat Med       Date:  2018-08-20       Impact factor: 53.440

Review 8.  Nanotechnology-based immunotherapies to combat cancer metastasis.

Authors:  Yuping Zhao; Muhammad Bilal; Maimoona Qindeel; Muhammad Imran Khan; Kuldeep Dhama; Hafiz M N Iqbal
Journal:  Mol Biol Rep       Date:  2021-08-23       Impact factor: 2.316

Review 9.  Comparing the effects of different cell death programs in tumor progression and immunotherapy.

Authors:  Michelle N Messmer; Annelise G Snyder; Andrew Oberst
Journal:  Cell Death Differ       Date:  2018-10-19       Impact factor: 15.828

10.  Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.

Authors:  Jiali Yu; Michael D Green; Shasha Li; Yilun Sun; Sara N Journey; Jae Eun Choi; Syed Monem Rizvi; Angel Qin; Jessica J Waninger; Xueting Lang; Zoey Chopra; Issam El Naqa; Jiajia Zhou; Yingjie Bian; Long Jiang; Alangoya Tezel; Jeremy Skvarce; Rohan K Achar; Merna Sitto; Benjamin S Rosen; Fengyun Su; Sathiya P Narayanan; Xuhong Cao; Shuang Wei; Wojciech Szeliga; Linda Vatan; Charles Mayo; Meredith A Morgan; Caitlin A Schonewolf; Kyle Cuneo; Ilona Kryczek; Vincent T Ma; Christopher D Lao; Theodore S Lawrence; Nithya Ramnath; Fei Wen; Arul M Chinnaiyan; Marcin Cieslik; Ajjai Alva; Weiping Zou
Journal:  Nat Med       Date:  2021-01-04       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.